As CMS embarks on CY 2025 rulemaking, the Alliance submitted a letter urging the Agency to support patient access to CTPs (skin substitutes), level the playing field for manufacturers, and reduce Medicare Part B costs by adopting a universal average sales price (ASP) reimbursement methodology for all CTP products. The Alliance voiced concern, again, about  the Agency's past bundling proposals, which would be detrimental to patients—particularly among patients with large and/or more complex wounds. 

Read More